| Volume: | 60,976,316 |
|---|---|
| Day's Low: | $18.12 |
| 52-wk Low: | $11.62 |
| Previous Close: | $18.11 |
| Dividend: | $0.16 |
| Market Cap: | 148,156,700 |
| Avg Volume: | 52,704,000 |
|---|---|
| Day's High: | $18.48 |
| 52-wk High: | $18.48 |
| Open Price: | $18.15 |
| Yield: | 3.49% |
| P/E (Forward): | 9.09 |
| 10:30 AM | 11/21/2009 | MARKET SNAPSHOT: Investors May Turn Defensive As Fizz Leaves Stocks |
| 9:16 AM | 11/20/2009 | Pfizer Executive:In Talks To Expand Licensing Pact With Aurobindo |
| 9:12 PM | 11/19/2009 | CORRECT:Justice Dept's Health-Care Fraud Caseload Nears 1,000 |
| 2:24 PM | 11/19/2009 | Abbott Hesitates To Promote Niaspan Study Due To FDA Rules |
| 9:16 AM | 11/19/2009 | CORRECT: (11/18)FDA Board Considers Prevnar Vaccine Safe, Effective |
| 2:45 PM | 11/18/2009 | UPDATE: Study Questions Utility Of Merck Cholesterol Drugs |
| 2:38 PM | 11/18/2009 | CORRECT:In Overhaul,Drug Industry Insider Sees 'Good, Bad, Ugly' |
| 11/20/2009 | Dell Tumbles 10%; Merck Gains |
| 11/20/2009 | A month into an acquisition, and Merck already sees a benefit. |
| 11/20/2009 | No more dog vomit in the cup holders. |
| 11/20/2009 | Pfizer's Generics Business Takes Shape |
| 11/20/2009 | Health Fraud Caseload Grows |
| 11/20/2009 | Market-trouncing returns could be written in these four stars. |
| 11/20/2009 | How make a quick $78,000 without lifting a finger. |
| Most Recent Quarter ($) | Same Quarter Last Year ($) | % Change | |
| EPS, Pro Forma | 0.51 | 0.62 | -17.74 |
| EPS, GAAP | 0.43 | 0.34 | 26.47 |
| Consensus Estimate | 0.48 | 0.60 | -20.00 |
| Trailing 12 Months | Year-Earlier Period | % Change | |
| EPS, Pro Forma | 2.18 | 2.42 | -9.92 |
| EPS, GAAP | 1.21 | 1.55 | -21.94 |
| Consensus Estimate | 2.02 | NA | NA |
| PFE | Industry Average | |
| P/E (TTM) | 15.17 | 16.90 |
| P/E (Forward) | 9.09 | 1.10 |
| PEG Ratio | -12.12 | 0.07 |
| Price/Sales | 2.71 | 3.05 |
| Beta | 0.71 | 0.73 |